---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-25-003916"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-01-28T23:59:59+00:00"
generated_at: "2026-05-27T08:30:19.073904+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# Calidi Biotherapeutics terminates SEPA with Yorkville; year-end cash $9.6M

## Summary
- Terminated Standby Equity Purchase Agreement with Yorkville effective Jan 23, 2025; no shares ever issued under $25M facility.
- Preliminary unaudited cash balance at Dec 31, 2024: approximately $9.6 million.
- Q4'24 capital: $9.5M from public offerings, $2.0M from warrants, $3.1M from ATM; additional $4.25M in Jan 2025.
- CEO states termination removes potential stock overhang, supports shareholder value.
- IND cleared for CLD-101 Phase 1b/2 trial for high-grade glioma; enrollment to start Q1 2025.

## SEC filing metadata
- accession: 0001493152-25-003916
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-01-28T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 1.02, 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000149315225003916/0001493152-25-003916-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000149315225003916/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-25-003916
- JSON: https://secwatch.observer/filing/0001493152-25-003916.json
- Plain text: https://secwatch.observer/filing/0001493152-25-003916.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.